12th November 2024

The MHRA Orange Guide

This update contains changes regarding Qualified Person Code of Practice.

12th November 2024

ASHP Injectable Drug Information

This update contains 4 new monographs and 121 revised monographs.

New monographs: Donanemab; Hydroxocobalamin; Lecanemab; Sodium Nitrite.

Revised monographs: Acetaminophen; Allopurinol Sodium; Alprostadil; Alteplase; Amikacin Sulfate; Amino Acids; Amiodarone Hydrochloride; Amphotericin B; Ampicillin Sodium; Ampicillin Sodium-Sulbactam Sodium; Argatroban; Ascorbic Acid; ASHP Injectable Drug Information – Notices and Editorial; ASHP Injectable Drug Information – Preface; ASHP Injectable Drug Information – Table of Contents; ASHP Injectable Drug Information – Users Guide; ASHP Injectable Drug Information-References; Bivalirudin; Bumetanide; BUPivacaine Hydrochloride; Buprenorphine Hydrochloride; Calcium Gluconate; Cangrelor Tetrasodium; CARBOplatin; Carmustine; CeFAZolin Sodium; Cefotaxime Sodium; CefoTEtan Disodium; CefOXitin Sodium; CefTAZidime; Cetuximab; Chloroprocaine Hydrochloride; ChlorproMAZINE Hydrochloride; Cisatracurium Besylate; CISplatin; Clevidipine; CloNIDine Hydrochloride; Coagulation Factor IX (Recombinant); Cyanocobalamin; Decitabine; Deferoxamine Mesylate; DexmedeTOMIDine Hydrochloride; DilTIAZem Hydrochloride; DOBUTamine Hydrochloride; DOPamine Hydrochloride; DOXOrubicin Hydrochloride; EPHEDrine Sulfate; EPINEPHrine Hydrochloride; Esmolol Hydrochloride; Fenoldopam Mesylate; FentaNYL Citrate; Floxuridine; Furosemide; Heparin Sodium; Hetastarch in Sodium Chloride 0.9%; HYDROmorphone Hydrochloride; Ifosfamide; Imipenem-Cilastatin Sodium; Insulin; Isoproterenol Hydrochloride; Ketamine Hydrochloride; Ketorolac Tromethamine; Labetalol Hydrochloride; LevETIRAcetam; LEVOleucovorin Calcium; Lidocaine Hydrochloride; LORazepam; Magnesium Sulfate; Mannitol; Meropenem; Methadone Hydrochloride; MethylPREDNISolone Sodium Succinate; Metoprolol Tartrate; Midazolam Hydrochloride; Milrinone Lactate; Morphine Sulfate; Nafcillin Sodium; Naloxone Hydrochloride; Neostigmine Methylsulfate; NiCARdipine Hydrochloride; Nitroglycerin; Norepinephrine Bitartrate; Octreotide Acetate; Oxacillin Sodium; Oxytocin; Pantoprazole Sodium; Pembrolizumab; Penicillin G Potassium; Penicillin G Sodium; PENTobarbital Sodium; Phentolamine Mesylate; Phenylephrine Hydrochloride; Phenytoin Sodium; Plazomicin Sulfate; Potassium Chloride; Pralidoxime Chloride; Promethazine Hydrochloride; Propofol; Propranolol Hydrochloride; Remifentanil Hydrochloride; RifAMPin; Rocuronium Bromide; ROPivacaine Hydrochloride; Sodium Acetate; Sodium Bicarbonate; Sodium Chloride; Sodium Nitroprusside; Sodium Thiosulfate; Sulbactam Sodium and Durlobactam Sodium; SUMAtriptan Succinate; Tacrolimus; Tedizolid Phosphate; Tenecteplase; Terbutaline Sulfate; Tigecycline; Tobramycin Sulfate; Torsemide; Tranexamic Acid; Vasopressin; Vecuronium Bromide; Verapamil Hydrochloride.

12th November 2024

BNF for Children

This update contains 7 significant changes, 5 dose changes, 1 new monograph, and 2 new preparations

Significant Changes:

• Antibacterials, principles of therapy: update to notifiable diseases reporting.
• Antibacterials, use for prophylaxis: updated guidance on secondary prevention of meningococcal disease and secondary prevention of pertussis.
• Borderline substances: oral nutritional supplements have been re-organised in a new section called Oral nutrition.
• Co-amoxiclav: update to structure of indications and dose section; tablet dose expression changed to co-amoxiclav (total of amoxicillin and clavulanic acid).
• Immunisation schedule: updated guidance for immunisation against influenza, and for pertussis in pregnancy.
• Pertussis vaccine: updated guidance for immunisation.
• Topical corticosteroids: update to the list of topical corticosteroid potencies.

Dose Changes:

• Ciprofloxacin [indication changed from prevention of secondary case of meningococcal meningitis to prevention of secondary case of meningococcal disease].
• Ivacaftor [update to dosing].
• Lithium carbonate [update to dosing].
• Lithium citrate [update to dosing].
• Lumacaftor with ivacaftor [update to dosing] .

New Monographs:

• Mepsevii® [vestronidase alfa].

New Preparations: Co-amoxiclav 1 g (875/125 mg) tablet; Co-amoxiclav 2.2 g (2000/200 mg) infusion.

12th November 2024

AHFS Drug Information

12th November 2024

Drug Compatibility Checker

12th November 2024

British National Formulary

This update contains 10 significant changes, 4 dose changes, 5 new monographs, and 5 new preparations.

Significant Changes:

• Antibacterials, principles of therapy: update to notifiable diseases reporting.
• Antibacterials, use for prophylaxis: updated guidance on secondary prevention of meningococcal disease and secondary prevention of pertussis.
• Borderline substances: oral nutritional supplements have been re-organised in a new section called Oral nutrition.
• Co-amoxiclav: update to structure of indications and dose section; tablet dose expression changed to co-amoxiclav (total of amoxicillin and clavulanic acid).
• Faricimab: new indication and dose for macular oedema secondary to retinal vein occlusion.
• Immunisation schedule: updated guidance for immunisation against influenza, and for pertussis in pregnancy.
• Lower urinary tract symptoms in males: new guidance.
• Oxytocin: risk of overdose during labour and childbirth [NPSA advice].
• Pertussis vaccine: updated guidance for immunisation.
• Topical corticosteroids: update to the list of topical corticosteroid potencies.

Dose Changes:

• Ciprofloxacin [indication changed from prevention of secondary case of meningococcal meningitis to prevention of secondary case of meningococcal disease].
• Lithium carbonate [update to dosing].
• Lithium citrate [update to dosing].
• Risankizumab [update to dosing].

New Monographs:

• Fabhalta® [iptacopan].
• Isoprenaline hydrochloride.
• Mepsevii® [vestronidase alfa].
• Obgemsa® [vibegron].
• Yselty® [linzagolix].

New Preparations: Ceyxa® [olanzapine]; Co-amoxiclav 1 g (875/125 mg) tablet; Co-amoxiclav 2.2 g (2000/200 mg) infusion; Metalyse® 5000 units (25 mg) [tenecteplase]; Xyquila® [olanzapine].